UNIVERSITY OF WASHINGTON

A study in JAMA Network Open followed 214 preterm infants treated with erythropoietin or placebo to age 10.4, finding no cognitive benefits. Term-born children showed better cognitive outcomes. The study underscores the need for well-designed phase III trials and preclinical testing in multiple animal models before human trials.

New research suggests pandemic isolation caused rapid brain aging in teen girls, with scans showing their brains aged 4.2 years faster than expected, compared to 1.4 years for boys. This accelerated cortical thinning, linked to depression and anxiety, may be due to girls' greater reliance on social interaction. The study raises questions about the long-term impact of such changes.

The RDCA-DAP, funded by the FDA and run by C-Path, has received new CF datasets from the Cystic Fibrosis Therapeutics Development Network, coordinated by Seattle Children’s Research Institute. These datasets aim to accelerate CF research and therapy development, enhancing the RDCA-DAP’s role in combating rare diseases.

Article lists affiliations and authors from various institutions including Nuffield Council on Bioethics, Stanford University, McGill University, National Institutes of Health, and more, across multiple countries.

Therapy-treated group showed decreased brain activity correlating with enhanced problem-solving; researchers attribute this to more efficient cognitive processing. Both groups improved in depression severity, but therapy-treated group specifically benefited in cognitive control-related symptoms. Early brain scan changes indicated long-term improvement in problem-solving and depression symptoms, suggesting potential for precision psychiatry.

CCR West celebrates its 40th anniversary with a focus on CAR T-cell therapy and precision medicine, featuring cutting-edge research and presentations by leading experts in rheumatology.

The Dog Aging Project (DAP), a $23M study by CSU and other institutions, seeks dogs to understand aging. It studies genetics, healthspan, and conducts a rapamycin trial. Owners can nominate dogs at DogAgingProject.org, contributing to research on extending dogs' healthy lives.

Brenda Flowers, Dr. Joyce Javier, Javier Alegre, Dr. Teresa Molina, Susan Rubio Rivera, Erica Thrash-Sall, Ilana Steinhauer, Melissa Robinson, Emilie Harmeyer, Anagha Talluri, Sanjana Buddi, D. Rashaan Gilmore, Susy Molano, Te Jay McGrath, Maurice Lee, Ilima Ho-Lastimosa, Jane Chung-Do, Linda Coleman, Tsu-Yin Wu, Carol Zernial, Daryl D. Quarles, Alex Sanchez, Arianna Innuritegui-Lint, Dr. Shreya Kangovi, Dr. Mary Wirshup, Edward Tepporn, Jose Che-Che Turrubiartez, Maria Gomez, Michael Klein, Gabriel Sanders, Tina Fleming, Lindsey Jorstad, Dr. Sarah Cusworth Walker, Kevin Williams, Angela Bannerman Ankoma, Sharon Conard-Wells, XinQi Dong, Suzanne Held, Alma McCormick, Yolo Akili Robinson, Angela Settle, Janeth Tapia, Becky Tuttle, Cante Waste Win Zephier, Terry Spitznagel, Leah Alexander, Katina Beard, Reverend Gerald Brown, Elizabeth Bustos, Steven Crane, Rogene Gee Calvert, Jacob Griffin, Monica Johnson, Jae Maldonado, Sarah Schoeder, Kate West, Patricia Solano, Mike Espel, Thelma Craig, Terri Richardson, DJ Ida, Steven E. Marcus, Sarah Miracle, Stephany Parker, Garron Rogers are leaders and organizations dedicated to addressing health disparities, mental health, substance abuse, domestic violence, and social determinants of health through innovative, community-based, and culturally responsive approaches. Their work spans across various communities, focusing on system change, equity, and empowerment to improve health outcomes and quality of life for underserved populations.

Psychedelics like psilocybin and MDMA show promise in treating mental health conditions, including anxiety and depression in cancer patients, with studies highlighting their potential for long-lasting effects. However, further research is needed to confirm safety and efficacy, and treatments are conducted in controlled environments with therapeutic support.

The article details a study on designing protein minibinders targeting αvβ6 integrin, using computational techniques, yeast display, and biophysical characterization. It includes the synthesis of PLN-74809, biotinylation of proteins, and structural analysis. The study also covers in vitro and in vivo binding assays, inhibition of TGF-β activation, and pharmacokinetic analysis in mice. Techniques like negative-stain EM, cryoEM, and lung mechanics assessment were used. The research aims to develop therapeutic strategies for diseases involving αvβ6 integrin.